RxDoctor Payments Data

John Yuhas

Psychiatric/Mental Health · Palm Springs, CANPI 1538833512

Payments from drug & device makers

$1,806in general payments, 2019–2025

Across 60 payments — averaging $30.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$841
  • Alkermes, Inc.$468
  • Johnson & Johnson$210
  • Otsuka America Pharmaceutical, Inc.$66
  • Teva Pharmaceuticals USA, Inc.$62
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$59
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$1,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,806 in reported general payments places this provider in the 75th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$45,323
Medicare patients
95
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl46$84,657
TrintellixVortioxetine Hydrobromide43$24,049
LexaproEscitalopram Oxalate11$4,862
Lurasidone Hcl24$1,948
Bupropion XlBupropion Hcl139$1,879
Duloxetine Hcl102$1,248
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine18$1,204
Trazodone Hcl151$1,064
Buspirone Hcl93$1,061
Vilazodone Hcl13$1,059
Venlafaxine Hcl ErVenlafaxine Hcl42$989
Lamotrigine139$971
Mirtazapine96$921
Aripiprazole77$853
Quetiapine Fumarate80$807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Lexapro$841$89,51957 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$24,04943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →